In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, J Cloos, G Ossenkoppele, B Gjertsen, B Øystein, C Heckman, M Heinäniemi, M Kontro, O Lohi

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)e604
JournalBlood cancer journal
Volume7
Issue number9
DOIs
Publication statusPublished - 8 Sep 2017

Cite this

Laukkanen, S., Grönroos, T., Pölönen, P., Kuusanmäki, H., Mehtonen, J., Cloos, J., ... Lohi, O. (2017). In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood cancer journal, 7(9), e604. https://doi.org/10.1038/bcj.2017.87